Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 513 participants.

Also called NCT02752412

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 513 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02752412
Other papers using this trial's data
  • Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial Diabetes, obesity & metabolism, 2020-09 DOI, PubMed 32072742

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02752412. Randomized; no masking; primary purpose treatment. Start 2016-05-17 (actual); primary completion 2018-10-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Acronym
LIXILAN JP-L
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Intervention (Drug)
Insulin glargine U100 (HOE901)
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02752412
Content hash
9ab9dc31224e1fa36f4299689445ac809f6db357b66ab7595ec9506e0877cff0